Supporting Oncology Care Through Molecular-Driven Cancer Navigation

Navexio supports healthcare professionals to help patients navigate complex diagnostic and treatment pathways, including access to advanced molecular testing, emerging therapies, and clinical trials - both within and, where appropriate, beyond traditional care pathways.

Navexio’s role is to complement the care team by identifying additional evidence-based options and supporting patients in accessing them, while respecting and reinforcing physician-directed care.

Navigation Across the Patient Journey

The oncology landscape continues to evolve rapidly, with increasing complexity. At the same time, system-level constraints including limited time, fragmented testing pathways, and access challenges can make it difficult to fully explore all clinically relevant options.

Navexio is designed to complement existing care by acting as a focused, specialized resource in precision oncology supporting both patients and their care teams.

How Navexio Supports HCPs

    • Service: Comprehensive audit of prior testing (eg. IHC, PCR, NGS, ctDNA) to identify missing, incomplete, or suboptimal biomarker assessments, including evaluation of panel selection and testing methodology.

    • How this supports HCPs: Saves time on detailed retrospective chart and biomarker review, and helps ensure no clinically relevant molecular insight is overlooked without requiring additional effort from the treating team.

    • Service: Coordination of advanced molecular testing, including tissue retrieval, sample logistics, and identification of best-fit laboratories and sequencing platforms (DNA vs RNA, panel selection).

    • How this supports HCPs: Offloads the operational and administrative complexity of ordering and coordinating advanced diagnostics, reducing back-and-forth with pathology departments and external labs.

    • Service: Structured review of molecular profiling results with synthesis of relevant evidence from peer-reviewed literature, clinical guidelines (e.g., NCCN, ESMO, ASCO), and emerging data. This includes highlighting potential clinical relevance of identified alterations, such as known associations with targeted therapies, resistance mechanisms, and prognostic insights

    • How this supports HCPs: Provides a consolidated, evidence-based summary of complex molecular findings, reducing the time required to review literature and contextual data, and supporting efficient clinical interpretation and decision-making by the treating team.

    • Service: Identification and prioritization of biomarker-driven clinical trials, along with evaluation of drug access pathways (on-label, off-label, compassionate use, and cross-border options). Navexio also supports outreach and coordination with clinical trial sites—including those outside the patient’s home institution—facilitating initial inquiries, eligibility clarification, and navigation of site-specific requirements.

    • How this supports HCPs: Reduces the significant administrative burden associated with identifying and coordinating clinical trial opportunities, including external site communication, paperwork, and logistics. This allows the care team to focus on clinical decision-making, while ensuring patients are efficiently connected to appropriate trial or access pathways.

    • Service: Dedicated oncology nurse support for patient education, care coordination, and ongoing guidance throughout the treatment journey.

    • How this supports HCPs: Reduces inbound patient questions and coordination demands on clinic staff, while reinforcing physician-directed care plans and improving overall patient preparedness and engagement.

An Evidence-Based Oncology Navigation and Scientific Approach

Navexio applies a rigorous, evidence-driven approach to cancer care by synthesizing molecular diagnostics, peer-reviewed literature, and real-world access pathways leveraging deep expertise in cancer biology and genomics to ensure each patient’s case is explored comprehensively and with scientific rigor.

Our reviews incorporate:

  • Peer-reviewed scientific literature

  • International clinical guidelines (e.g., NCCN, ESMO, ASCO)

  • Clinical trial databases and emerging translational data

We apply systematic approaches to the review of molecular and diagnostic data, including:

  • Assessment of genomic alterations (e.g., SNVs, CNVs, gene fusions)

  • Consideration of testing methodologies (DNA vs RNA sequencing)

  • Contextualization of findings using recognized actionability frameworks (e.g., AMP/ASCO/CAP, ESCAT)

  • Evaluation of tumor biology, heterogeneity, and potential resistance mechanisms

Our role is to synthesize complex and rapidly evolving scientific information into structured, clinically relevant insights that can support informed discussions between patients and their treating teams.

Collaborative, Ethical, and Patient-Centered Integration into Clinical Care

Navexio works in alignment with treating physicians and multidisciplinary teams to support evidence-based patient care without replacing clinical decision-making while upholding strict standards of ethics, privacy, transparency, and regulatory compliance, and ensuring all engagement is conducted with appropriate patient consent and respect for the integrity of the healthcare system.

When to Consider Navexio and How to Refer

Navexio may be a valuable resource in clinical scenarios where additional diagnostic insight, evidence synthesis, or access navigation could support patient care.

Referral is simple and flexible:

  • Patients may be referred directly by their physician or may self-refer

  • No administrative burden is placed on the clinical team

  • Navexio manages coordination of services that you support with the patient

All engagements are conducted with appropriate patient consent, and outputs are structured to support efficient discussion with the treating team.

Refer a Patient